Table 2.
Risk factors associated with survival and acute and chronic GVHD after an HLA-matched sibling transplant
| Outcome | No. of events/evaluable | HR (95% CI) | P |
|---|---|---|---|
| Overall survival | |||
| Conditioning regimen | |||
| Cy/Flu/ATG | 11/135 | 1.00 | |
| Cy/ATG | 51/593 | 1.36 (0.70-2.64) | .37 |
| Cy ± Flu | 27/142 | 2.83 (1.38-5.82) | .005 |
| Bu/Cy | 13/85 | 2.44 (1.07-5.57) | .03 |
| Age, y | |||
| <30 | 63/758 | 1.00 | |
| ≥30 | 39/197 | 2.74 (1.81-4.14) | <.001 |
| Recipient CMV serostatus | |||
| Negative | 10/252 | 1.00 | |
| Positive | 91/688 | 2.81 (1.45-5.45) | .002 |
| Grade II-IV acute GVHD | |||
| Conditioning regimen | |||
| Cy/Flu/ATG | 15/134 | 1.00 | |
| Cy/ATG | 76/592 | 1.27 (0.70-2.29) | .44 |
| Cy ± Flu | 15/140 | 1.22 (0.56-2.65) | .61 |
| Bu/Cy | 9/85 | 1.30 (0.53-3.20) | .57 |
| Transplant period | |||
| 2000-2008 | 32/411 | 1.00 | |
| 2009-2014 | 83/540 | 2.20 (1.41-3.42) | .001 |
| Chronic GVHD | |||
| Conditioning regimen | |||
| Cy/Flu/ATG | 13/134 | 1.00 | |
| Cy/ATG | 106/589 | 2.25 (1.20-4.20) | .01 |
| Cy ± Flu | 20/141 | 1.96 (0.94-4.06) | .07 |
| Bu/Cy | 19/85 | 3.11 (1.45-6.68) | .004 |
| Age, y | |||
| <30 | 114/756 | 1.00 | |
| ≥30 | 44/193 | 1.80 (1.25-2.59) | .002 |